We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

23 hedge funds and large institutions have $5.86M invested in Gyre Therapeutics in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more capital invested

Capital invested by funds: $2.48M → $5.86M (+$3.38M)

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

35% more funds holding

Funds holding: 17 → 23 (+6)

0.46% more ownership

Funds ownership: 3.49% → 3.94% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $11K

Holders
23
Holders Change
+6
Holders Change %
+35.29%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
4
Reduced
–
Closed
6
Calls
–
Puts
$11K
Net Calls
-$11K
Net Calls Change
-$1.18M

Top Buyers

1
SCM
Sio Capital Management
New York
+$1.69M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.31M
3
BlackRock
BlackRock
New York
+$785K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$383K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$156K

Top Sellers

1
Simplex Trading
Simplex Trading
Illinois
-$156K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$80K
3
FPF
FNY Partners Fund
New York
-$26K
4
Wells Fargo
Wells Fargo
California
-$2.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sio Capital Management
New York
$1.64M +$1.69M +47,090 New
Renaissance Technologies
2
Renaissance Technologies
New York
$1.58M +$1.31M +36,520 +416%
BlackRock
3
BlackRock
New York
$806K +$785K +21,867 +1,734%
EWM
4
Essex Woodlands Management
Texas
$372K – – –
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$372K +$383K +10,662 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$204K +$156K +4,350 +294%
NMC
7
NEA Management Company
Maryland
$202K – – –
ZIM
8
Zacks Investment Management
Illinois
$147K +$151K +4,209 New
UBS Group
9
UBS Group
Switzerland
$122K +$8.72K +243 +7%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$107K +$110K +3,052 New
VKH
11
Virtu KCG Holdings
New York
$103K +$106K +2,957 New
Tudor Investment Corp
12
Tudor Investment Corp
Connecticut
$67K +$69.4K +1,932 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$57K +$59.5K +1,658 New
TSS
14
Two Sigma Securities
New York
$55K +$56.9K +1,586 New
Deutsche Bank
15
Deutsche Bank
Germany
$16K +$17.2K +480 New
CG
16
Cutler Group
California
$4K +$4.31K +120 New
Group One Trading
17
Group One Trading
Illinois
$2K +$2.19K +61 New
Simplex Trading
18
Simplex Trading
Illinois
– -$156K -2,216 Closed
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
– -$80K -1,128 Closed
FPF
20
FNY Partners Fund
New York
– -$26K -373 Closed
Wells Fargo
21
Wells Fargo
California
– -$2.4K -67 Closed
Barclays
22
Barclays
United Kingdom
– +$144 +4 New

GYRE Hedge Fund Activity: Q2 2017 in Review

23 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2017, worth a combined $5.86M — up 136% from $2.48M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new GYRE positions and 6 closed out — a net gain of 6 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.69M. The largest seller was Simplex Trading, exiting entirely with an estimated $156K sold.

  • 23 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2017, up from 17 in Q1 2017.
  • Funds reported $5.86M of Gyre Therapeutics stock for Q2 2017, up 136% quarter-over-quarter.
  • 12 funds opened new Gyre Therapeutics positions in Q2 2017 and 6 closed out, a net change of +6 holders.
  • The largest Gyre Therapeutics buyer in Q2 2017 was Sio Capital Management, an estimated $1.69M added.
  • The largest Gyre Therapeutics seller in Q2 2017 was Simplex Trading, an estimated $156K sold.

Based on aggregated 13F filings for Q2 2017.